Improvement in disease severity and quality of life in patients with atopic dermatitis (AD) treated with dupilumab for up to 18 months: Real-world evidence from the PROSE registry

Improvement in disease severity and quality of life in patients with atopic dermatitis (AD) treated with dupilumab for up to 18 months: Real-world evidence from the PROSE registry Meeting Abstract

publication date

September 1, 2022

webpage

Web of Science

published in

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Journal

start page

AB68

end page

AB68

volume

87

issue

3